Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2013 1
2018 1
2020 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.
Smoragiewicz M, Bogaerts J, Calvo E, Marabelle A, Perrone A, Seymour L, Shalabi A, Siu LL, Tabernero J, Giaccone G; task force on Methodology for the Development of Innovative Cancer Therapies. Smoragiewicz M, et al. Ann Oncol. 2018 Nov 1;29(11):2175-2182. doi: 10.1093/annonc/mdy398. Ann Oncol. 2018. PMID: 30202892 Free article. Review.
The Methodology for the Development of Innovative Cancer Therapies task force considered aspects of the design and conduct of early studies of combinations of immunotherapy agents during their 2018 meeting. The task force defined the relevant data to justify combina …
The Methodology for the Development of Innovative Cancer Therapies task force considered aspects of the design and conduct of early s …
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies.
Kummar S, Doroshow JH, Tomaszewski JE, Calvert AH, Lobbezoo M, Giaccone G; Task Force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Kummar S, et al. Eur J Cancer. 2009 Mar;45(5):741-6. doi: 10.1016/j.ejca.2008.10.024. Epub 2008 Dec 16. Eur J Cancer. 2009. PMID: 19091546 Free PMC article. Review.
The Methodology for the Development of Innovative Cancer Therapies (MDICT) task force has been established as an expert forum to develop practical guidance on the development of innovative anticancer agents, in particular targeted agents. The task force recently add …
The Methodology for the Development of Innovative Cancer Therapies (MDICT) task force has been established as an expert forum to deve …
Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT).
Smoragiewicz M, Adjei AA, Calvo E, Tabernero J, Marabelle A, Massard C, Tang J, de Vries EGE, Douillard JY, Seymour L; task force on Methodology for the Development of Innovative Cancer Therapies. Smoragiewicz M, et al. Clin Cancer Res. 2020 Jun 1;26(11):2461-2465. doi: 10.1158/1078-0432.CCR-19-3136. Epub 2020 Feb 21. Clin Cancer Res. 2020. PMID: 32086344
EXPERIMENTAL DESIGN: The Methodology for the Development of Innovative Cancer Therapies Task Force 2019 included experts from academia, nonprofit organizations, industry, and regulatory agencies. ...
EXPERIMENTAL DESIGN: The Methodology for the Development of Innovative Cancer Therapies Task Force 2019 included experts from academi …
Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.
Seymour LK, Calvert AH, Lobbezoo MW, Eisenhauer EA, Giaccone G; task force on Methodology for the Development of Innovative Cancer Therapies. Seymour LK, et al. Eur J Cancer. 2013 May;49(8):1808-14. doi: 10.1016/j.ejca.2013.01.014. Epub 2013 Feb 18. Eur J Cancer. 2013. PMID: 23428669
The Methodology for the Development of Innovative Cancer Therapies (MDICT) task force considered aspects of the design and conduct of early (phase I and II) studies of combinations of molecular targeted agents during their 2012 meeting. The task force defined necess …
The Methodology for the Development of Innovative Cancer Therapies (MDICT) task force considered aspects of the design and conduct of …